Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

Form 4	IERAPEUTICS (Corp									
July 21, 2015 FORM 4 Check this box if no longer subject to Section 16. Form 4 or The form 4 or				RITIES AND EXCHANGE C shington, D.C. 20549 GES IN BENEFICIAL OWN SECURITIES 6(a) of the Securities Exchange tility Holding Company Act of				ERSHIP OF Act of 1934, 1935 or Section	OMB APPROVAL OMB 3235-028 Number: January 3 Expires: January 3 200 Estimated average burden hours per response 0		
See Instr 1(b).		30(h)	of the In	ivestment	Compar	ny Ac	t of 194()			
(Print or Type]	Responses)										
ZACCARDELLI DAVID Symbol				r Name and Ticker or Trading D THERAPEUTICS Corp 1				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date of (Month/D C/O UNITED THERAPEUTICS CORP., 1040 SPRING STREET				-				Director 10% Owner Officer (give title Other (specify below) EVP & Chief Operating Officer			
Filed(Mor				endment, Date Original nth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
SILVER SF	PRING, MD 2091	0						Person	ore than One Rej	Jorung	
(City)	(State)	(Zip)	Tab	le I - Non-D	Derivative	Secur	ities Acqu	ired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common Stock	07/21/2015			Code V $M^{(1)}$	Amount 928	(D) A	Price \$ 57.15		D		
Common Stock	07/21/2015			D <u>(1)</u>	928	D	\$ 175.17	1,375	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: UNITED THERAPEUTICS Corp - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	omof		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. l De Sec (In
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Share Tracking Award	\$ 57.15	07/21/2015		M <u>(1)</u>		928	03/15/2011	03/15/2020	Common Stock	928	

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
ZACCARDELLI DAVID C/O UNITED THERAPEUTICS CORP. 1040 SPRING STREET SILVER SPRING, MD 20910			EVP & Chief Operating Officer					
Signatures								
/s/ John S. Hess, Jr. under Power of Attorney	07/21/20)15						
**Signature of Reporting Person	Date							
Evaluation of Deenser								

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Exercise of a cash-settled share tracking award pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.